Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory … – Markets Insider
|
Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR–T Stem Cell Memory …
Markets Insider SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that the first patient has been … |
